Defining the relative and combined contribution of CTCF and CTCFL to genomic regulation.
3D chromatin architecture
CTCF
CTCFL
Cancer
Chromatin insulation
Cohesin
Gene regulation
Loop extrusion
Journal
Genome biology
ISSN: 1474-760X
Titre abrégé: Genome Biol
Pays: England
ID NLM: 100960660
Informations de publication
Date de publication:
11 05 2020
11 05 2020
Historique:
received:
12
12
2019
accepted:
16
04
2020
entrez:
13
5
2020
pubmed:
13
5
2020
medline:
2
4
2021
Statut:
epublish
Résumé
Ubiquitously expressed CTCF is involved in numerous cellular functions, such as organizing chromatin into TAD structures. In contrast, its paralog, CTCFL, is normally only present in the testis. However, it is also aberrantly expressed in many cancers. While it is known that shared and unique zinc finger sequences in CTCF and CTCFL enable CTCFL to bind competitively to a subset of CTCF binding sites as well as its own unique locations, the impact of CTCFL on chromosome organization and gene expression has not been comprehensively analyzed in the context of CTCF function. Using an inducible complementation system, we analyze the impact of expressing CTCFL and CTCF-CTCFL chimeric proteins in the presence or absence of endogenous CTCF to clarify the relative and combined contribution of CTCF and CTCFL to chromosome organization and transcription. We demonstrate that the N terminus of CTCF interacts with cohesin which explains the requirement for convergent CTCF binding sites in loop formation. By analyzing CTCF and CTCFL binding in tandem, we identify phenotypically distinct sites with respect to motifs, targeting to promoter/intronic intergenic regions and chromatin folding. Finally, we reveal that the N, C, and zinc finger terminal domains play unique roles in targeting each paralog to distinct binding sites to regulate transcription, chromatin looping, and insulation. This study clarifies the unique and combined contribution of CTCF and CTCFL to chromosome organization and transcription, with direct implications for understanding how their co-expression deregulates transcription in cancer.
Sections du résumé
BACKGROUND
Ubiquitously expressed CTCF is involved in numerous cellular functions, such as organizing chromatin into TAD structures. In contrast, its paralog, CTCFL, is normally only present in the testis. However, it is also aberrantly expressed in many cancers. While it is known that shared and unique zinc finger sequences in CTCF and CTCFL enable CTCFL to bind competitively to a subset of CTCF binding sites as well as its own unique locations, the impact of CTCFL on chromosome organization and gene expression has not been comprehensively analyzed in the context of CTCF function. Using an inducible complementation system, we analyze the impact of expressing CTCFL and CTCF-CTCFL chimeric proteins in the presence or absence of endogenous CTCF to clarify the relative and combined contribution of CTCF and CTCFL to chromosome organization and transcription.
RESULTS
We demonstrate that the N terminus of CTCF interacts with cohesin which explains the requirement for convergent CTCF binding sites in loop formation. By analyzing CTCF and CTCFL binding in tandem, we identify phenotypically distinct sites with respect to motifs, targeting to promoter/intronic intergenic regions and chromatin folding. Finally, we reveal that the N, C, and zinc finger terminal domains play unique roles in targeting each paralog to distinct binding sites to regulate transcription, chromatin looping, and insulation.
CONCLUSION
This study clarifies the unique and combined contribution of CTCF and CTCFL to chromosome organization and transcription, with direct implications for understanding how their co-expression deregulates transcription in cancer.
Identifiants
pubmed: 32393311
doi: 10.1186/s13059-020-02024-0
pii: 10.1186/s13059-020-02024-0
pmc: PMC7212617
doi:
Substances chimiques
CCCTC-Binding Factor
0
CTCFL protein, human
0
Ctcfl protein, mouse
0
DNA-Binding Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108Subventions
Organisme : NCI NIH HHS
ID : P01 CA229086
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016087
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM122515
Pays : United States
Organisme : NIGMS NIH HHS
ID : 1R35GM122515
Pays : United States
Organisme : NCI NIH HHS
ID : P01CA229086
Pays : United States
Commentaires et corrections
Type : ErratumIn
Références
Cell. 2008 Feb 8;132(3):422-33
pubmed: 18237772
Mol Cell Biol. 2015 Oct;35(19):3436-45
pubmed: 26169830
Clin Cancer Res. 2011 Jul 1;17(13):4267-76
pubmed: 21558405
Clin Cancer Res. 2009 Sep 1;15(17):5323-37
pubmed: 19723653
Oncogene. 2007 Jun 28;26(30):4394-403
pubmed: 17260018
Cell. 2015 Dec 17;163(7):1611-27
pubmed: 26686651
Transl Oncol. 2018 Oct;11(5):1213-1219
pubmed: 30081298
Bioinformatics. 2012 Jan 15;28(2):282-3
pubmed: 22113082
Nucleic Acids Res. 2009 Jul;37(Web Server issue):W202-8
pubmed: 19458158
Nucleic Acids Res. 2014 Dec 1;42(21):13026-38
pubmed: 25378304
Cell. 2017 Oct 5;171(2):305-320.e24
pubmed: 28985562
Cancer Res. 2005 Sep 1;65(17):7763-74
pubmed: 16140944
Prostate. 2014 Feb;74(2):164-76
pubmed: 24123052
Bioinformatics. 2011 Jun 15;27(12):1696-7
pubmed: 21486936
Chromosome Res. 2009;17(2):201-14
pubmed: 19308701
Cell Rep. 2013 May 30;3(5):1678-1689
pubmed: 23707059
Nucleic Acids Res. 2016 Jul 8;44(W1):W160-5
pubmed: 27079975
Mol Cell Biol. 2010 May;30(10):2473-84
pubmed: 20231363
Invest Ophthalmol Vis Sci. 2013 Feb 05;54(2):1061-9
pubmed: 23329662
Nucleic Acids Res. 2018 Aug 21;46(14):7097-7107
pubmed: 29860503
Cell Syst. 2016 Jul;3(1):95-8
pubmed: 27467249
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5978-86
pubmed: 17062669
Discov Med. 2017 Aug;24(130):19-29
pubmed: 28950072
Cell Rep. 2016 May 31;15(9):2038-49
pubmed: 27210764
Genome Biol. 2014;15(12):550
pubmed: 25516281
Mol Cell. 2017 Jun 1;66(5):711-720.e3
pubmed: 28529057
Gene. 2017 Sep 20;629:29-34
pubmed: 28764977
Cancers (Basel). 2018 May 25;10(6):
pubmed: 29799499
Mol Cell. 2019 Nov 7;76(3):412-422.e5
pubmed: 31522988
Proc Natl Acad Sci U S A. 2020 Jan 28;117(4):2020-2031
pubmed: 31937660
Cell Res. 2017 Nov;27(11):1365-1377
pubmed: 29076501
Clin Cancer Res. 2011 Apr 15;17(8):2170-80
pubmed: 21296871
Nat Commun. 2018 Feb 7;9(1):542
pubmed: 29416042
PLoS One. 2010 Nov 08;5(11):e13872
pubmed: 21079786
Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):E6456-65
pubmed: 26499245
Nucleic Acids Res. 1997 Feb 1;25(3):466-74
pubmed: 9016583
Mol Cancer Res. 2019 Oct;17(10):2051-2062
pubmed: 31292201
Biochem Pharmacol. 2006 Nov 30;72(11):1577-88
pubmed: 16854382
EMBO J. 2017 Dec 15;36(24):3573-3599
pubmed: 29217591
Cell. 2017 May 4;169(4):693-707.e14
pubmed: 28475897
Cancer Sci. 2012 Sep;103(9):1617-24
pubmed: 22676270
Elife. 2018 Jan 29;7:
pubmed: 29376829
Genome Biol. 2015 Aug 14;16:161
pubmed: 26268681
PLoS One. 2019 May 20;14(5):e0217002
pubmed: 31107884
Curr Opin Genet Dev. 2014 Feb;24:8-15
pubmed: 24657531
Cell. 2017 May 18;169(5):930-944.e22
pubmed: 28525758
Annu Rev Genet. 2001;35:673-745
pubmed: 11700297
Oncogene. 2019 Mar;38(12):2092-2107
pubmed: 30442981
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Nat Methods. 2015 Oct;12(10):963-965
pubmed: 26280331
Cell Syst. 2016 Jul;3(1):99-101
pubmed: 27467250
BMC Genomics. 2017 Jan 5;18(1):22
pubmed: 28056762
Genome Biol. 2008;9(9):R137
pubmed: 18798982
BMC Cancer. 2017 May 19;17(1):352
pubmed: 28525978
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Mol Cell Biol. 2011 Jun;31(11):2174-83
pubmed: 21444719
Bioinformatics. 2015 Jul 15;31(14):2382-3
pubmed: 25765347
Semin Cancer Biol. 2002 Oct;12(5):399-414
pubmed: 12191639
Nature. 2015 Jul 9;523(7559):240-4
pubmed: 26030525
Mol Cell. 2010 May 28;38(4):576-89
pubmed: 20513432
Proc Natl Acad Sci U S A. 2018 Jul 17;115(29):E6697-E6706
pubmed: 29967174
Cancer Res. 2007 Feb 1;67(3):1239-45
pubmed: 17283160
PLoS Genet. 2008 Aug 29;4(8):e1000169
pubmed: 18769711
Cancer Cell Int. 2018 Oct 5;18:154
pubmed: 30323717
Database (Oxford). 2017 Jan 1;2017(1):
pubmed: 28365736
J Am Soc Nephrol. 2005 Jun;16(6):1632-44
pubmed: 15843474
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Oncogenesis. 2019 Aug 12;8(8):41
pubmed: 31406110
Proc Natl Acad Sci U S A. 2015 Jun 16;112(24):7542-7
pubmed: 26034287
Genes Dev. 2014 Apr 1;28(7):723-34
pubmed: 24696455
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6806-11
pubmed: 12011441
Clin Cancer Res. 2007 Mar 15;13(6):1713-9
pubmed: 17363524
Br J Cancer. 2008 Feb 12;98(3):571-9
pubmed: 18195709
Mol Cell. 2019 Nov 7;76(3):395-411.e13
pubmed: 31522987
Nat Chem Biol. 2020 Mar;16(3):257-266
pubmed: 31792445
Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8309-14
pubmed: 18550811
Cancer Immun. 2007 Dec 21;7:21
pubmed: 18095639
Epigenetics Chromatin. 2012 Jun 18;5(1):8
pubmed: 22709888
Oncogene. 2014 Nov 6;33(45):5225-37
pubmed: 24336328
Nature. 2019 Aug;572(7771):676-680
pubmed: 31391581
Nat Methods. 2012 Oct;9(10):999-1003
pubmed: 22941365